Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?

[1]  C. Azzoli,et al.  Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. , 2021, European journal of cancer.

[2]  S. Friesland,et al.  Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. , 2021, European journal of cancer.

[3]  Jingjing Liu,et al.  Factors related to rapid progression of non‐small cell lung cancer in Chinese patients treated using single‐agent immune checkpoint inhibitor treatment , 2020, Thoracic cancer.

[4]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[5]  E. Smit,et al.  How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  E. Garon,et al.  Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer. , 2019, Lung cancer.

[7]  V. Torri,et al.  Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors , 2019, ESMO Open.

[8]  Gregory Riely,et al.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Tabuchi,et al.  Impact of Comorbidities on Survival in Gastric, Colorectal, and Lung Cancer Patients , 2018, Journal of epidemiology.

[10]  C. Weber,et al.  Neutrophils as protagonists and targets in chronic inflammation , 2017 .

[11]  J. Gilbert,et al.  Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases , 2015, Inflammatory bowel diseases.

[12]  Sarah A. Teichmann,et al.  Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis , 2014, Cell reports.

[13]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.

[14]  S. Peters,et al.  OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 , 2017 .